ATE465751T1 - Verfahren zur vorbeugung und linderung angiogener erkrankungen durch impfung mit dem rezeptor für gbs-toxin (cm101) - Google Patents
Verfahren zur vorbeugung und linderung angiogener erkrankungen durch impfung mit dem rezeptor für gbs-toxin (cm101)Info
- Publication number
- ATE465751T1 ATE465751T1 AT01906979T AT01906979T ATE465751T1 AT E465751 T1 ATE465751 T1 AT E465751T1 AT 01906979 T AT01906979 T AT 01906979T AT 01906979 T AT01906979 T AT 01906979T AT E465751 T1 ATE465751 T1 AT E465751T1
- Authority
- AT
- Austria
- Prior art keywords
- gbs toxin
- toxin receptor
- preventing
- vaccination
- relieving
- Prior art date
Links
- 239000003053 toxin Substances 0.000 title abstract 7
- 231100000765 toxin Toxicity 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 230000002491 angiogenic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 108700012359 toxins Proteins 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17987000P | 2000-02-02 | 2000-02-02 | |
| PCT/US2001/003662 WO2001056598A2 (en) | 2000-02-02 | 2001-02-02 | Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE465751T1 true ATE465751T1 (de) | 2010-05-15 |
Family
ID=22658332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01906979T ATE465751T1 (de) | 2000-02-02 | 2001-02-02 | Verfahren zur vorbeugung und linderung angiogener erkrankungen durch impfung mit dem rezeptor für gbs-toxin (cm101) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20020061846A1 (de) |
| EP (1) | EP1198246B1 (de) |
| JP (1) | JP2003521523A (de) |
| KR (1) | KR20020001817A (de) |
| CN (1) | CN100400100C (de) |
| AT (1) | ATE465751T1 (de) |
| AU (2) | AU782853B2 (de) |
| BR (1) | BR0104357A (de) |
| CA (1) | CA2369050A1 (de) |
| DE (1) | DE60141938D1 (de) |
| IL (1) | IL145710A0 (de) |
| MX (1) | MXPA01009917A (de) |
| NO (1) | NO20014772L (de) |
| WO (1) | WO2001056598A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803448B1 (en) * | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
| US8609614B2 (en) * | 1998-07-22 | 2013-12-17 | Vanderbilt University | GBS toxin receptor compositions and methods of use |
| GB0227026D0 (en) * | 2002-11-20 | 2002-12-24 | Molecular Skincare Ltd | Psoriasis diagnostics and therapeutics |
| EP2468729B1 (de) | 2003-10-15 | 2013-12-25 | Ube Industries, Ltd. | Neues Indazolderivat |
| JP2022523295A (ja) * | 2019-01-25 | 2022-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 発疱剤および苛性ガスの毒性作用を緩和する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| US5010062A (en) * | 1989-09-25 | 1991-04-23 | Vanderbilt University | Therapeutic agent and method of inhibiting vascularization of tumors |
| US5858991A (en) * | 1997-01-29 | 1999-01-12 | Vanderbilt University | Facilitation of wound healing with CM101/GBS toxin |
| US6803448B1 (en) * | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
| WO2000005375A1 (en) * | 1998-07-22 | 2000-02-03 | Vanderbilt University | Gbs toxin receptor |
-
2001
- 2001-02-02 EP EP01906979A patent/EP1198246B1/de not_active Expired - Lifetime
- 2001-02-02 BR BR0104357-9A patent/BR0104357A/pt not_active IP Right Cessation
- 2001-02-02 DE DE60141938T patent/DE60141938D1/de not_active Expired - Lifetime
- 2001-02-02 AU AU34817/01A patent/AU782853B2/en not_active Ceased
- 2001-02-02 MX MXPA01009917A patent/MXPA01009917A/es unknown
- 2001-02-02 AT AT01906979T patent/ATE465751T1/de not_active IP Right Cessation
- 2001-02-02 CA CA002369050A patent/CA2369050A1/en not_active Abandoned
- 2001-02-02 JP JP2001556497A patent/JP2003521523A/ja active Pending
- 2001-02-02 CN CNB018005993A patent/CN100400100C/zh not_active Expired - Fee Related
- 2001-02-02 IL IL14571001A patent/IL145710A0/xx unknown
- 2001-02-02 WO PCT/US2001/003662 patent/WO2001056598A2/en not_active Ceased
- 2001-02-02 KR KR1020017012595A patent/KR20020001817A/ko not_active Withdrawn
- 2001-02-02 US US09/776,865 patent/US20020061846A1/en not_active Abandoned
- 2001-10-01 NO NO20014772A patent/NO20014772L/no unknown
-
2009
- 2009-10-16 AU AU2009227821A patent/AU2009227821A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN100400100C (zh) | 2008-07-09 |
| NO20014772L (no) | 2001-11-12 |
| WO2001056598A3 (en) | 2002-02-14 |
| IL145710A0 (en) | 2002-07-25 |
| DE60141938D1 (de) | 2010-06-10 |
| AU2009227821A1 (en) | 2009-11-05 |
| AU782853B2 (en) | 2005-09-01 |
| US20020061846A1 (en) | 2002-05-23 |
| WO2001056598A2 (en) | 2001-08-09 |
| CA2369050A1 (en) | 2001-08-09 |
| BR0104357A (pt) | 2002-05-21 |
| JP2003521523A (ja) | 2003-07-15 |
| CN1372474A (zh) | 2002-10-02 |
| EP1198246B1 (de) | 2010-04-28 |
| NO20014772D0 (no) | 2001-10-01 |
| EP1198246A2 (de) | 2002-04-24 |
| KR20020001817A (ko) | 2002-01-09 |
| MXPA01009917A (es) | 2003-08-01 |
| AU3481701A (en) | 2001-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT833911E (pt) | Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao | |
| WO2002058717A3 (en) | Methods for treating rheumatoid arthritis using il-17 antagonists | |
| EP0671927A4 (de) | Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialviru. | |
| DE59800285D1 (de) | Verfahren zur ex vivo-Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper | |
| MXPA02007756A (es) | Anticuerpos que aglutinan interleuqina-18 humana y metodos de fabricacion y uso. | |
| ECSP066681A (es) | Formas sólidas de anticuerpos anti-egfr | |
| ATE373719T1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
| MXPA03004793A (es) | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. | |
| DK1140170T3 (da) | Antistoffragmenter til topisk behandling af öjensygdomme | |
| EP0794195A3 (de) | Antikörper BV10A4H2 | |
| DE60040651D1 (de) | Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien | |
| BR9809656A (pt) | Composição imunopotencializante | |
| IS4922A (is) | Fjölpeptíð sem geta myndað formgerðir mótefnisvakabindinga með sérvirkni fyrir resus D mótefnisvaka, DNA-ið sem táknar þau og aðferðin til að búa þautil og notkun | |
| FI972703A0 (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
| ATE272409T1 (de) | Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate | |
| BR0314369A (pt) | Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado | |
| ES2114064T3 (es) | Inmunoanalisis para la deteccion de colageno o fragmentos de colageno. | |
| DE60141938D1 (de) | Verfahren zur vorbeugung und linderung angiogener erkrankungen durch impfung mit dem rezeptor für gbs-toxin (cm101) | |
| WO2002059154A3 (en) | Neutralizing human monoclonal antibodies against hiv-1, their production and uses | |
| AU4396401A (en) | Composition and method for the prevention and/or the treatment of allergy | |
| PT804219E (pt) | Composicoes de inibina e metodos para a sua utilizacao | |
| WO2002020619A3 (en) | HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) | |
| ATE310750T1 (de) | Verotoxin b untereinheit zur immunisierunug | |
| ES2164231T3 (es) | Antigeno de helicobacter pylori. | |
| NZ554142A (en) | Antibody production method comprising inserting antigen releasing device into mammal so antibodies are released into its milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |